Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07209449) titled 'A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer' on Oct. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Memorial Sloan Kettering Cancer Center
Condition:
Endometrial Cancer
Intervention:
Drug: Abemaciclib
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: October 1, 2025
Target Sample Size: 75
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07209449
P...